A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer,Annals of Oncology

当前位置： X-MOL 学术 › Ann. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer
Annals of Oncology ( IF 50.5 ) Pub Date : 2017-07-19 , DOI: 10.1093/annonc/mdx284
N. Katakami , E. Felip , D.R. Spigel , J.-H. Kim , M. Olivo , M. Guo , H. Nokihara , J. C.-H. Yang , N. Iannotti , M. Satouchi , F. Barlesi

Eribulin is a microtubule dynamics inhibitor with a novel mechanism of action. This phase 3 study aimed to compare overall survival (OS) in patients with heavily pretreated non-small cell lung cancer (NSCLC) receiving eribulin to treatment of physician’s choice (TPC).

中文翻译：

一项随机，开放标签，多中心，第3期研究，用于比较eribulin与晚期非小细胞肺癌患者选择医师治疗的疗效和安全性

Eribulin是一种具有新作用机制的微管动力学抑制剂。这项3期研究旨在比较接受eribulin进行高度预处理的非小细胞肺癌（NSCLC）患者的整体生存率（OS）与医师选择治疗（TPC）的生存率。

更新日期：2017-09-18

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>